Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial

Topline results expected in second half of 2021 Topline results expected in second half of 2021

Go here to read the rest:
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial

Related Post